GSK2126458

Omipalisib (GSK2126458) is an orally active and highly selective inhibitor of PI3K with Kis of 0.019 nM/0.13 nM/0.024 nM/0.06 nM and 0.18 nM/0.3 nM for p110α/β/δ/γ, mTORC1/2, respectively. Omipalisib has anti-cancer activity .


Cat. No.: EX-A003	Purity: >98%

	Chemical structure of GSK2126458

For research only, Do not use for Human!

Size	Unit Price (US$)	Stock
100mg	430	In-stock
250mg	840	In-stock
500mg	1300	In-stock
1g	2150	In-stock
2g	3400	In-stock
3g	4100	In-stock

Send PO to E-mail:[email protected]; or Fax:+86 020 81619670

Discount Request


Synonyms	Omipalisib
CAS No.	1086062-66-9
Purity	>98%
Formula	C25H17F2N5O3S
Mol Weight	505.496
Color	white to yellow
State	solid
Solubility	Soluble in DMSO
Shelf Life	>3 years if stored properly
Storage	Powder 4℃ 2 years; In solvent -20℃ 1 month;
Shipping	Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Reference:	[1]. Knight SD, et al. Discovery of GSK2126458, a Highly Potent Inhibitor of PI3K and the Mammalian Target of Rapamycin. ACS Med. Chem. Lett. 2010, 1 (1), 39-43. [2]. Greger JG, et al. Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations. Mol Cancer Ther. 2012 Apr;11(4):909-20. [3]. Kim HG, et al. Discovery of a potent and selective DDR1 receptor tyrosine kinase inhibitor. ACS Chem Biol. 2013 Oct 18;8(10):2145-50.
CoA	CoA of GSK2126458

Smiles:	COC1=NC=C(C=C1NS(=O)(=O)C1=CC=C(F)C=C1F)C1=CC=C2N=CC=C(C3=CC=NN=C3)C2=C1


		Search